Emergent BioSolutions, Inc. provided earnings guidance for the fiscal 2015, 2016 and 2020 and for the first quarter of fiscal 2016. For the year 2015, the company expects total revenues of $520 million to $525 million, a 16% increase over 2014. This growth is driven by continued robust BioThrax sales, accounting for approximately $294 million. The company anticipates GAAP net income of $60 million to $64 million, or $1.27 to $1.35 per diluted share, the midpoint of which represents a 69% increase over 2014. On a non-GAAP basis, the company anticipates full year 2015 adjusted net income of $73 million to $77 million, or $1.54 to $1.63 per diluted share, the midpoint of which represents a 38% increase over 2014. The company expects EBITDA of $130 million to $134 million, a 43% increase over 2014 and year-end cash of approximately $310 million.

For the year 2016, the company expects total revenues of $600 million to $630 million, driven by growth in BioThrax sales which are anticipated to be between $305 million to $320 million, continued domestic and international sales of the other Biodefense division products, and continued robust development funding through contracts and grants revenues. The company also forecasts full year 2016 GAAP net income of $75 million to $85 million, non-GAAP adjusted net income of $90 million to $100 million, and EBITDA of $150 million to $160 million. The company's outlook for 2016 includes the impact of a successful spin-off of Aptevo Therapeutics in mid-2016 and continuous delivery of BioThrax to the CDC under an anticipated follow-on, multi-year procurement contract, but does not include any estimates for BioThrax deliveries from Building 55, the company's large scale BioThrax manufacturing facility, or any estimates for potential new corporate development or other M&A transactions.

For the first quarter of 2016, the company anticipates total revenues of $105 million to $120 million.

For the year 2020, the company expects annual revenue of $1 billion of which more than 10% of revenue from ex-US markets expected and net income CAGR of more than 20%.